Movectro: Withdrawal of the marketing authorisation application
On 8 February 2011, Merck Serono Europe Limited officially notified the Committee for Medicinal Products for Human Use (CHMP) that it wishes to withdraw its application for a marketing authorisation for Movectro, for the treatment of relapsing-remitting multiple sclerosis.
|International non-proprietary name (INN) or common name||
|Date of withdrawal||
|Company making the application|
Withdrawal assessment report for Movectro (PDF/997.77 KB)Adopted
First published: 30/03/2011
Last updated: 30/03/2011
Movectro: Withdrawal letter (PDF/1.9 MB)
First published: 23/02/2011
Last updated: 23/02/2011
Merck Serono Europe Limited withdraws its marketing authorisation application for Movectro (cladribine) (PDF/49.46 KB)
First published: 17/02/2011
Last updated: 17/02/2011
Related information on withdrawals
A question-and-answer (Q&A) document provides a summary of the CHMP's evaluation of the medicine at the time of the withdrawal of the application, and includes a link to the company's formal withdrawal letter (withdrawal letter Doc. type, leave the 'Author' in properties blank).
An assessment report is published when the application is withdrawn after the first stage of the CHMP's evaluation is completed ('day 120').